Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Clidinium (compound)

Summary
General Info

PubChem

PubChem Compound 11397907

PubChem Compound 11397907

Name:	clidinium
PubChem Compound ID:	11397907
Molecular formula:	C₂₂H₂₆NO₃⁺
Molecular weight:	351.448 g/mol

DrugBank

Identification

Name:	clidinium
Name (isomeric):	DB00771
Drug Type:	small molecule
Brand:	Quarzan
Brand name mixture:	Pro Chlorax(Chlordiazepoxide Hydrochloride + Clidinium Bromide), Librax(Chlordiazepoxide Hydrochloride + Clidinium Bromide), Apo-Chlorax Cap(Chlordiazepoxide Hydrochloride + Clidinium Bromide)
Category:	Parasympatholytics, Anticholinergic Agents, Antiarrhythmic Agents, Antispasmodics
CAS number:	7020-55-5

Pharmacology

Indication:	For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Pharmacology:	Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Mechanism of Action:	Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.
Toxicity:	Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Trimethobenzamide	Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
Donepezil	Possible antagonism of action
Secretin	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
Haloperidol	The anticholinergic increases the risk of psychosis and tardive dyskinesia

Trimethobenzamide	Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
Donepezil	Possible antagonism of action
Secretin	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
Haloperidol	The anticholinergic increases the risk of psychosis and tardive dyskinesia
Pramlintide	Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur.
Galantamine	Possible antagonism of action
Potassium Chloride	Anticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives.
Trospium	Trospium and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Triprolidine	Triprolidine and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.

Targets

Muscarinic acetylcholine receptor M1